News About: Pharm. Industry
Green Cross’ fresh start with new name ‘GC’
Green Cross Holdings has changed its company name to GC.
With participation of Chairman Il-Sup Huh, employees and their family, GC(Green Cross Holdings) held a kick-off meeting for the new year of 2018 and declared i...
No. of GMP-certified drug manufacturers increased by 52 for past 10 years
The government has reconstructed the pharmaceutical industry, but the number of companies is reportedly rather increasing in the field.
The ‘2017 Food and Drug Statistics Year Book’ published by the Ministry of Food ...
Drug advertising reviews for online media increased by 20% compared to the last year
The number of drug advertising reviews in 2017 was 3,861 cases, which was increased by 518 compared to the last year(3,343 cases).
According to the 2017 Drug Adverting Review Status aggregated by the Korea Pharmaceut...
Patent Linkage System made sales increased by KRW 0.9 to 1.4 billion sales on generic companies
In 2 years of the Patent Linkage System , generic manufacturers had sales increased by approximately KRW 0.9 to 1.4 billion, but original companies had a decrease by KRW 1.6 to 2.2 billion sales. Also, it was analyzed...
Janssen Korea appoints President Jenny Zheng
Janssen Korea announced appointment of President Jenny Zheng as Area Managing Director, Korea, Taiwan and Hong Kong from 1 January 2018.
President Jenny Zheng is a sales and marketing expert with more than 20-year ex...
Rumors about next Chair of the KPBMA, what is the reality?
Heng-Myung Lee, Chair of the Board of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA), decided not to continue his position, there have been many rumors about the next chair.
First of all, th...
It’s time for pharma & biotech industry to answer, “2018 is Year with Outcomes”
Pharmaceutical companies have set 2018 as the ‘Year with Outcomes’ from researches and developments they have conducted so far.
Each pharmaceutical company has not officially revealed their management plan yet, but a...
Hanall, “We received USD 30 million upfront payment for technology export from Roivant”
Hanall Biohparma(CEO Seung-Gook Park, Jae-Choon Yoon) announced “We received the USD 30 million(approx. KRW 32.4 billion) upfront payment for its autoimmune disease antibody(HL161) technology agreement from Roivant Sc...
Alteogen challenges to KRW 1.8 trillion acromegaly treatment market with Severance Hospital
Alteogen(Soon-Jae Park), a company developing antibody biobetters, announced on the 22nd that the company has signed a co-development agreement of an acromegaly treatment using NexP™-based growth hormone receptors wit...
SK to target the KRW 1 trillion global market of sleep disorder treatments
SK Biopharmaceuticals announced on the 21st the company completed the NDA(New Drug Application) process to the U.S. FDA for SKL-N05(generic name: Solriamfetol) with U.S. Jazz Pharmaceuticals, the world’s leading compa...
